Latest Period
Q1 2026
Security Snapshot
NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (NRXP) Institutional Ownership
CUSIP: 629444209
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
31
Shares (Excl. Options)
6,161,670
Price
$2.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- NRXP on Nasdaq
- Shares outstanding
- 35,443,612
- Price per share
- $2.91
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 6,161,670
- Total reported value
- $13,153,346
- % of total 13F portfolios
- 0%
- Share change
- +403,404
- Value change
- -$926,366
- Number of holders
- 31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- NRXP - NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 629444209.
- 31 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 28 to 31 between Q4 2025 and Q1 2026.
- Reported value moved from $14,169,868 to $13,153,346.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 31 institutions filings for Q1 2026.
Security key
629444209
Latest holder period
Q1 2026
13F holders
31
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
NRXP full holder history
NRX Pharmaceuticals, Inc. SEC filings
NRX Pharmaceuticals, Inc. company facts
NRX Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 629444209:
Significant Owners of NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (NRXP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| B Group, Inc. | 13% | $8,820,000 | 3,000,000 | The B Group, Inc. | 18 Aug 2025 | |||
| Anson Funds Management LP | 4.9% | -49% | $3,855,556 | +$292,512 | 1,736,737 | +8.2% | Anson Funds Management LP | 31 Mar 2026 |
As of 31 Mar 2026, 31 institutional investors reported holding 6,161,670 shares of NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (NRXP). This represents 17% of the company’s total 35,443,612 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (NRXP) together control 17% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| B Group, Inc. | 8.5% | 3,000,000 | 4.7% | $6,390,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 1,160,184 | 0% | 0% | $2,471,192 |
| AdvisorShares Investments LLC | 1.2% | 420,467 | +28% | 0.16% | $895,595 |
| COMMONWEALTH EQUITY SERVICES, LLC | 1.1% | 397,431 | +8.4% | 0% | $846,530 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 310,112 | +42% | 0% | $660,609 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 169,580 | 0% | 0% | $361,205 |
| Bleakley Financial Group, LLC | 0.33% | 117,204 | 0% | 0% | $249,645 |
| BlackRock, Inc. | 0.28% | 98,995 | +20% | 0% | $210,860 |
| STATE STREET CORP | 0.25% | 86,984 | 0% | 0% | $185,276 |
| XTX Topco Ltd | 0.22% | 78,733 | 0% | $167,701 | |
| JANE STREET GROUP, LLC | 0.12% | 44,152 | +16% | 0% | $94,044 |
| NORTHERN TRUST CORP | 0.12% | 43,469 | +50% | 0% | $92,589 |
| Headlands Technologies LLC | 0.11% | 39,394 | 0.01% | $83,909 | |
| Chicago Partners Investment Group LLC | 0.1% | 34,479 | +3.2% | 0% | $102,403 |
| AXQ CAPITAL, LP | 0.09% | 33,211 | 0.01% | $70,739 | |
| Virtu Financial LLC | 0.09% | 31,785 | 0% | $68,000 | |
| UBS Group AG | 0.07% | 25,227 | +613% | 0% | $53,734 |
| Schonfeld Strategic Advisors LLC | 0.06% | 19,876 | 0% | $42,335 | |
| Ethos Financial Group, LLC | 0.04% | 15,900 | +34% | 0% | $33,867 |
| SJBENEN ADVISORY, LLC | 0.04% | 15,000 | 0% | 0.03% | $31,950 |
| MORGAN STANLEY | 0.03% | 10,028 | -0.01% | 0% | $21,360 |
| ROYAL BANK OF CANADA | 0.01% | 2,509 | +25% | 0% | $5,000 |
| SBI Securities Co., Ltd. | 0.01% | 2,500 | 0% | 0% | $5,325 |
| WELLS FARGO & COMPANY/MN | 0.01% | 2,350 | +18% | 0% | $5,006 |
| SUMMIT SECURITIES GROUP LLC | 0% | 1,135 | 0% | $2,418 |
Institutional Holders of NRX Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (NRXP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 6,161,670 | $13,153,346 | -$926,366 | $2.13 | 31 |
| 2025 Q4 | 5,235,517 | $14,169,868 | +$3,242,026 | $2.71 | 28 |
| 2025 Q3 | 3,956,630 | $13,043,325 | +$3,167,783 | $3.30 | 24 |
| 2025 Q2 | 2,994,368 | $9,761,438 | +$2,410,566 | $3.26 | 25 |
| 2025 Q1 | 2,260,524 | $4,602,262 | +$2,464,504 | $2.05 | 22 |
| 2024 Q4 | 1,048,642 | $2,306,847 | +$754,487 | $2.20 | 25 |
| 2024 Q3 | 714,327 | $1,207,232 | +$328,214 | $1.69 | 18 |
| 2024 Q2 | 510,346 | $1,261,065 | +$1,261,065 | $2.44 | 18 |